- Home
- GNTA vs CGTX Comparison
GNTA vs CGTX Comparison
Compare GNTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | CGTX |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | Italy | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 94.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNTA | CGTX |
|---|---|---|
| Price | $0.69 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 57.7K | ★ 1.5M |
| Earning Date | 03-24-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.22 |
| 52 Week High | $10.00 | $3.83 |
Technical Indicators
Market Signals| Indicator | GNTA | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 59.45 |
| Support Level | $0.61 | $1.01 |
| Resistance Level | $0.75 | $1.19 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 48.15 | 80.00 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.